Apnimed is a late-stage clinical pharmaceutical company focused on developing and commercializing novel oral therapies for sleep-related breathing diseases. Their primary product candidate, AD109 (Oxnimbi), is an investigational treatment for obstructive sleep apnea (OSA) that aims to enhance upper airway muscle activity. The company has submitted a New Drug Application (NDA) for Oxnimbi to the FDA, which has been accepted for review.
Per S-1 disclosure; % may not sum to 100% when ownership is nested, multi-class, or reported on different bases.
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | $38.5M | $8.0M | Not provided |
| YoY Growth | +381.3% | - | - |
| Adjusted Net Loss | -$128.2M | -$111.3M | Not provided |
| Margin % | -333.0% | -1391.3% | - |
Based on price range midpoint and most recent fiscal year data.
The company operates in the pharmaceutical industry, specifically targeting treatments for obstructive sleep apnea. Apnimed competes with companies such as ResMed and Philips.
Proceeds from the IPO are expected to be used for advancing the clinical development of Oxnimbi and for general corporate purposes.
No broker information available yet
Check back later for updates
Reported by users or publicly disclosed. Information is for reference only.